Connect with us


Merck Invests Over 300 Million Euros in a New Research Center in Germany

Merck invests over 300 million euros in a new biotech research center in Germany, part of a larger 1.5 billion euro investment program for Darmstadt. The center, to open in 2027, focuses on antibody production, mRNA applications, and biotech products. Merck aims to advance scientific progress for global health, following recent global investments totaling over €2 billion.




Merck continues to invest in biotechnology. The pharmaceutical multinational has announced that it will allocate more than 300 million euros to the launch of a new research center in Germany. Specifically , the complex will be located at the group’s headquarters in Darmstadt.

The project is part of an investment program being developed by the German city, for which Merck has contributed around 1.5 billion euros until 2025. The new building will open its doors in 2027 and will employ 550 workers .

With the new investment, Merck will provide solutions in the production of antibodies , mRNA applications and products for biotechnology production, among other research. “With this investment, we are enabling scientific progress for the benefit of millions of patients and customers around the world,” said Belén Garijo, CEO of Merck, in a statement.

Merck to focus on antibody production, mRNA applications and biotech products

The Advanced Research Center of the pharmaceutical group brings together key research for the development of new medicines. The company is also engaged in research into cell culture media and pharmaceutical formulation and purification aids, as well as digital reference materials.

In recent years, Merck has made several investments on a global scale. Last March the group announced that it would disburse another 300 million euros, but for a plant in South Korea specialized in the production of bioprocessing. All in all, Merck has been announcing investments of more than €2 billion since 2020 with the aim of expanding the capabilities and possibilities of biological sciences to meet the growing demand for medicines worldwide.

The Merck group accumulated net sales of 20.99 billion euros in 2023, 1.6% less than in the previous fiscal year, while its gross operating result (ebitda) fell 14.2%, to 5.9 millions of euros. By 2024, the pharmaceutical company plans to return to the path of growth through sales in its Life Science division and the recovery of the semiconductor materials market.


(Featured image by RephiLe water via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.